News | August 31, 2022
Cipla (EU) to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
New mass spectrometry instrument and consumables launch during IMSC 2022
The existing hospital premises has the scope to further scale up the bed capacity as and when required in the future with minimal Capex.
This industry-academia collaboration will provide students with an opportunity to participate in research activities with multiple international universities and scientists
The book “Science behind Suryanamaskar” has been compiled by the AIIA’s Department of Swasthavritta and Yoga.
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
The unit has filed 2 Derma products and 1 MDI product.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
